International Journal Of Immunopathology And Pharmacology

International Journal Of Immunopathology And Pharmacology

国际免疫病理学和药理学杂志

  • 3区 中科院分区
  • Q2 JCR分区

期刊简介

《International Journal Of Immunopathology And Pharmacology》是由SAGE Publications Inc.出版社于1988年创办的英文国际期刊(ISSN: 2058-7384,E-ISSN: 2058-7384),该期刊长期致力于病理学领域的创新研究,主要研究方向为Immunology and Microbiology-Immunology。作为SCIE收录期刊(JCR分区 Q2,中科院 3区),本刊采用OA开放获取模式(OA占比1%),以发表病理学领域等方向的原创性研究为核心(研究类文章占比92.21%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在77篇,确保学术质量与前沿性。成果覆盖Web of Science、Scopus等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

International Journal Of Immunopathology And Pharmacology审稿周期约为 15 Weeks 。该刊近年被列入国际预警名单,年发文量约77篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 77 发文量

中科院分区

中科院 SCI 期刊分区 2023年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
3区
PATHOLOGY 病理学 PHARMACOLOGY & PHARMACY 药学 IMMUNOLOGY 免疫学
3区 3区 4区

中科院 SCI 期刊分区 2022年12月升级版

Top期刊 综述期刊 大类学科 小类学科
医学
4区
IMMUNOLOGY 免疫学 PATHOLOGY 病理学 PHARMACOLOGY & PHARMACY 药学
4区 4区 4区

JCR分区

按JIF指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q3 105 / 181

42.3%

学科:PATHOLOGY SCIE Q2 27 / 88

69.9%

学科:PHARMACOLOGY & PHARMACY SCIE Q2 136 / 354

61.7%

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q2 71 / 181

61.05%

学科:PATHOLOGY SCIE Q2 41 / 88

53.98%

学科:PHARMACOLOGY & PHARMACY SCIE Q2 136 / 354

61.72%

CiteScore

CiteScore SJR SNIP CiteScore 排名
CiteScore:4 SJR:0.611 SNIP:0.581
学科类别 分区 排名 百分位
大类:Pharmacology, Toxicology and Pharmaceutics 小类:Pharmacology Q3 174 / 313

44%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Immunology and Allergy Q3 141 / 233

39%

大类:Pharmacology, Toxicology and Pharmaceutics 小类:Immunology Q3 156 / 236

34%

期刊发文

  • Monomorphic epitheliotropic intestinal T-cell lymphoma may mimic intestinal inflammatory disorders.

    Author: Tian S1, Xiao SY1,2, Chen Q1, Liu H1, Ping J3.

    Journal: Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419829387. doi: 10.1177/2058738419829387.

  • Heat stress combined with lipopolysaccharide alter the activity and superficial molecules of peripheral monocytes.

    Author: Luo J1, Chen Y1, Ding C1, Qiu J1, Chen Y1, Lin Y1, Su L2, Jiang D1.

    Journal: Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419828891. doi: 10.1177/2058738419828891.

  • Tripterine up-regulates miR-223 to alleviate lipopolysaccharide-induced damage in murine chondrogenic ATDC5 cells.

    Author: Li X1, Wei W1, Zhao Z1, Lv S1.

    Journal: Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738418824521. doi: 10.1177/2058738418824521.

  • Possible treatment for cutaneous lichen planus: An in vitro anti-inflammatory role of Angelica polysaccharide in human keratinocytes HaCaT.

    Author: Wang J1, Chen G1, Shi T1, Wang Y1, Guan C1.

    Journal: Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738418821837. doi: 10.1177/2058738418821837.

  • Blocking of checkpoint receptor PD-L1 aggravates osteoarthritis in macrophage-dependent manner in the mice model.

    Author: Liu S1, Mi J2, Liu W1, Xiao S1, Gao C3.

    Journal: Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738418820760. doi: 10.1177/2058738418820760.

  • LncRNA SNHG3 promotes cell growth by sponging miR-196a-5p and indicates the poor survival in osteosarcoma.

    Author: Chen J1, Wu Z1, Zhang Y2.

    Journal: Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738418820743. doi: 10.1177/2058738418820743.

  • Effect of Chinese herbal compound GAPT on the early brain glucose metabolism of APP/PS1 transgenic mice.

    Author: Mana L1,2, Feng H1,3, Dong Y1,4, Wang Y1,2, Shi J1,5, Tian J1,5, Wang P1,2.

    Journal: Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419841482. doi: 10.1177/2058738419841482.

  • MiR-516a-5p inhibits the proliferation of non-small cell lung cancer by targeting HIST3H2A.

    Author: Ye XY1, Xu L2, Lu S1, Chen ZW1.

    Journal: Int J Immunopathol Pharmacol. 2019 Jan-Dec;33:2058738419841481. doi: 10.1177/2058738419841481.